Catalyst

Slingshot members are tracking this event:

BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL at the International Conference on Opioids

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BDSI

100%

Additional Information

Additional Relevant Details
Results showed prescriptions of Suboxone decreased from a weekly consistent peak of more than 1,600 to less than 100 within one month of the switch, while BUNAVAIL prescriptions increased from a low of 19 to approximately 600. This approximate 63 percent reduction in overall prescriptions in the plan remained throughout the measurement period, which may result in a savings of approximately $14 million to the state budget.  This real-world switch with a more than 60 percent reduction in overall buprenorphine prescriptions in the state suggests that a significant amount of prior product use may not have been used for the intended patient (a phenomenon known as diversion) or for its intended purpose (i.e., for the maintenance treatment of opioid dependence) as opposed to misuse or abuse of the product.
http://bdsi.investor...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Buprenorphine, Bunavail, Suboxone